Scale Up And Manufacturing Of Self-Amplifying RNA-LNPs For A COVID-19 Vaccine Using The NanoAssemblr® GMP System
Source: Precision NanoSystems
![GettyImages-1275317360-lab-cell-gene-research-scientist-development-discovery GettyImages-1275317360-lab-cell-gene-research-scientist-development-discovery](https://vertassets.blob.core.windows.net/image/100451ff/100451ff-667b-4d2a-8734-b1a05c527c23/375_250-gettyimages_1275317360_lab_cell_gene_research_scientist_development_discovery.jpg)
Objectives:
- To scale up SARS-CoV-2 self-amplifying RNA-Lipid nanoparticle using PNI developed ionizable lipid and formulation from 0.2, to 50 mg scale using PNI’s Manufacturing Platform (Ignite™, Blaze™, GMP NanoAssemblr®)
- A phase I trial for saRNA Vaccine requires 50 mg scale
- To optimize the down-stream processing (TFF/Sterile filtration)
- TFF type, Material, MWCO
- Processing buffers
- TFF shear rate
- TFF scalability
- To select a lead saRNA-LNP formulation and define a manufacturing process based on formulation activity, stability, scalability, repeatability and critical process parameters
access the Poster!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Precision NanoSystems
This website uses cookies to ensure you get the best experience on our website. Learn more